ESTRO 2024 - Abstract Book

S1126

Clinical - Gynaecology

ESTRO 2024

Conclusion:

Pembrolizumab plus CCRT showed a statistically significant and clinically meaningful improvement in PFS and a favorable trend in OS compared with placebo plus CCRT in patients with high-risk LACC. Pembrolizumab plus CCRT had a manageable safety profile, with most treatment-related AEs occurring during combination therapy compared with pembrolizumab monotherapy. These findings indicate that pembrolizumab plus CCRT can be considered as a potential new standard of care for this high-risk population.

Keywords: cervical cancer, chemoradiotherapy, pembrolizumab